000131062 001__ 131062
000131062 005__ 20240228145601.0
000131062 0247_ $$2doi$$a10.1016/j.bbmt.2017.07.015
000131062 0247_ $$2pmid$$apmid:28754546
000131062 0247_ $$2ISSN$$a1083-8791
000131062 0247_ $$2ISSN$$a1523-6536
000131062 0247_ $$2altmetric$$aaltmetric:23227720
000131062 037__ $$aDKFZ-2017-06129
000131062 041__ $$aeng
000131062 082__ $$a610
000131062 1001_ $$aLisenko, Katharina$$b0
000131062 245__ $$aComparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.
000131062 260__ $$a[S.l.]$$bElsevier Health Sciences$$c2017
000131062 3367_ $$2DRIVER$$aarticle
000131062 3367_ $$2DataCite$$aOutput Types/Journal article
000131062 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525773059_20626
000131062 3367_ $$2BibTeX$$aARTICLE
000131062 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131062 3367_ $$00$$2EndNote$$aJournal Article
000131062 520__ $$aHigh-dose melphalan (HDM) and autologous blood stem cell transplantation (ABSCT) is an effective treatment for transplantation-eligible patients with systemic light chain (AL) amyloidosis. Whereas most centers use granulocyte colony-stimulating factor (G-CSF) alone for mobilization of peripheral blood stem cells (PBSC), the application of mobilization chemotherapy might offer specific advantages. We retrospectively analyzed 110 patients with AL amyloidosis who underwent PBSC collection. Major eligibility criteria included age <70 years and cardiac insufficiency New York Heart Association ≤III°. Before mobilization, 67 patients (61%) had been pretreated with induction therapy, including 17 (15%) patients who had received melphalan. Chemo-mobilization was performed with either cyclophosphamide, doxorubicin, dexamethasone (CAD)/G-CSF (n = 78, 71%); ifosfamide/G-CSF (n = 14, 13%); or other regimens (n = 8, 7%). AL amyloidosis patients with predominant heart involvement and/or status post heart transplantation were mobilized with G-CSF only (n = 10, 9%). PBSC collection was successful in 101 patients (92%) at first attempt. The median number of CD34+ cells was 8.7 (range, 2.1 to 45.5) × 106 CD34+/kg collected in a median of 1 leukapheresis (LP) session. Compared with G-CSF-only mobilization, a chemo-mobilization with CAD/G-CSF or ifosfamide/G-CSF had a positive impact on the number of collected CD34+ cell number/kg per LP (P <.001, multivariate). Melphalan-containing previous therapy and higher age had a significant negative impact on quantity of collected CD34+ cells. Median common toxicity criteria (CTC) grade of nonhematologic toxicity was II (range, 0 to IV). Life-threatening CTC grade IV adverse events were observed in 3 patients with no fatalities. Cardiovascular events were observed in 17 patients (22%) upon CAD/G-CSF mobilization (median CTC: grade 3; range, 1 to 4). Toxicity in patients undergoing ifosfamide/G-CSF mobilization was higher than in with those who received G-CSF-only mobilization. HDM and ABSCT were performed in 100 patients. Compared with >6.5 × 106 transplanted CD34+ cells/kg, an ABSCT with <3 × 106 CD34+ cells/kg was associated with a longer duration to leukocyte reconstitution >1 × 109/L and a reduced platelet count <150 × 109/L 1 year after ASCT. Our results show that CAD chemotherapy is very effective in PBSC mobilization and has a tolerable toxicity profile in AL amyloidosis patients. A further toxicity reduction by omission of doxorubicin might be considered. Because of advanced nonhematologic toxicity, ifosfamide administration cannot be recommended. However, G-CSF mobilization alone is also safe and effective. Considering the hematopoietic reconstitution and long-term stem cell function, our results provide a rationale to collect and transplant as many as >6.5 × 106 CD34+ cells/kg, if feasible with reasonable effort.
000131062 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000131062 588__ $$aDataset connected to CrossRef, PubMed,
000131062 7001_ $$aWuchter, Patrick$$b1
000131062 7001_ $$aHansberg, Marion$$b2
000131062 7001_ $$aMangatter, Anja$$b3
000131062 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b4$$udkfz
000131062 7001_ $$aHo, Anthony D$$b5
000131062 7001_ $$aGoldschmidt, Hartmut$$b6
000131062 7001_ $$aHegenbart, Ute$$b7
000131062 7001_ $$aSchönland, Stefan$$b8
000131062 773__ $$0PERI:(DE-600)2057605-5$$a10.1016/j.bbmt.2017.07.015$$gVol. 23, no. 11, p. 1870 - 1878$$n11$$p1870 - 1878$$tBiology of blood and marrow transplantation$$v23$$x1083-8791$$y2017
000131062 909CO $$ooai:inrepo02.dkfz.de:131062$$pVDB
000131062 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000131062 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000131062 9141_ $$y2017
000131062 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131062 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOL BLOOD MARROW TR : 2015
000131062 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131062 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131062 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131062 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000131062 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000131062 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131062 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131062 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131062 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131062 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131062 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131062 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000131062 980__ $$ajournal
000131062 980__ $$aVDB
000131062 980__ $$aI:(DE-He78)C060-20160331
000131062 980__ $$aUNRESTRICTED